Dr. David Dalrymple - Statement about the SyncroPatch 384PE
“As a leading ion channel contract research organization running one of the most comprehensive ranges of ion channel assays, SB Drug Discovery has been impressed with the flexibility and reliability of the SyncroPatch 384PE (a predecessor model of SyncroPatch 384i), enabling development of a range of varied and complex ion channel assay for both high throughput screening and hit-to-lead profiling purposes. The SyncroPatch has proven to be a crucial addition to SB’s ion channel capabilities and in partnership with expert advice from Nanion’s support team has enabled SB to advance its ion channel capabilities to the forefront of ion channel drug discovery research..“
Dr. David Dalrymple
Business Development Director at SB Drug Discovery
![12.08.2022: Publication Alert - Discovery of Novel 7-Hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide Derivatives with Potent and Selective Antifungal Activity against Cryptococcus Species](/images/Images_tiff_jpg_png/Corporate_Blog_Press_Releases/220812_blog_image_Discovery%20of%20Novel%207-Hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide%20Derivatives%20with%20Potent%20and%20Selective%20Antifungal%20Activity%20against%20Cryptococcus%20Species.jpg)
